Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25596306 | 0.84 | OPRK1 (0.42) | ESR1ESR2OPRK1OPRD1TAAR1 | |
| SCHEMBL25596402 | 0.81 | PCNA (0.50) | ESR1ESR2OPRK1OPRD1TAAR1 | |
| SCHEMBL25596176 | 0.79 | TAAR1 (0.47) | ESR1ESR2OPRK1OPRD1TAAR1 | |
| SCHEMBL25596407 | 0.78 | ESR1 (0.47) | ESR1ESR2OPRK1OPRD1TAAR1 | |
| SCHEMBL12447831 | 0.67 | TAAR1 (0.53) | ESR1ESR2OPRK1TAAR1SLC6A2 | |
| SCHEMBL25596288 | 0.67 | PCNA (0.51) | ESR1ESR2OPRK1OPRD1ADRB2 | |
| SCHEMBL25596213 | 0.66 | TAAR1 (0.57) | ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL12809685 | 0.66 | OPRK1 (0.54) | ESR1ESR2OPRK1OPRD1 | |
| SCHEMBL9260666 | 0.66 | TAAR1 (0.56) | ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL25596305 | 0.65 | TAAR1 (0.50) | ESR1ESR2OPRK1OPRD1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | ESR1 4421/4885ESR2 4494/4885OPRK1 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.